Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

A Personalized Approach to Managing Patients With an Ileal Pouch-Anal Anastomosis.

Ardalan ZS, Sparrow MP.

Front Med (Lausanne). 2020 Jan 29;6:337. doi: 10.3389/fmed.2019.00337. eCollection 2019. Review.

2.

Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease.

Gibson DJ, Ward MG, Rentsch C, Friedman AB, Taylor KM, Sparrow MP, Gibson PR.

Aliment Pharmacol Ther. 2020 Mar;51(6):612-628. doi: 10.1111/apt.15643. Epub 2020 Jan 21. Review.

PMID:
31961001
3.

Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response.

Sparrow MP, Papamichael K, Ward MG, Riviere P, Laharie D, Paul S, Roblin X.

J Crohns Colitis. 2019 Sep 24. pii: jjz162. doi: 10.1093/ecco-jcc/jjz162. [Epub ahead of print]

PMID:
31549158
4.

Dietary fat and the faecal microbiome: where collinearity may lead to incorrect attribution of effects to fat.

Ardalan ZS, Sparrow MP, Muir JG, Gibson PR.

Gut. 2019 Sep 6. pii: gutjnl-2019-319628. doi: 10.1136/gutjnl-2019-319628. [Epub ahead of print] No abstract available.

PMID:
31492690
5.

Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes.

Julsgaard M, Hvas CL, Gearry RB, Gibson PR, Fallingborg J, Sparrow MP, Bibby BM, Connell WR, Brown SJ, Kamm MA, Lawrance IC, Vestergaard T, Svenningsen L, Baekdal M, Kammerlander H, Walsh A, Boysen T, Bampton P, Radford-Smith G, Kjeldsen J, Andrews JM, Subramaniam K, Moore GT, Jensen NM, Connor SJ, Wildt S, Wilson B, Ellard K, Christensen LA, Bell SJ.

Inflamm Bowel Dis. 2020 Jan 1;26(1):93-102. doi: 10.1093/ibd/izz110.

PMID:
31141607
6.

Comparison of Adalimumab Serum Drug Levels When Delivered by Pen Versus Syringe in Patients With Inflammatory Bowel Disease. An International, Multicentre Cohort Analysis.

Little RD, Chu IE, van der Zanden EP, Flanagan E, Bell SJ, Gibson PR, Sparrow MP, Shelton E, Connor SJ, Roblin X, Ward MG.

J Crohns Colitis. 2019 Dec 10;13(12):1527-1536. doi: 10.1093/ecco-jcc/jjz103.

PMID:
31094417
7.

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.

Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA.

Clin Gastroenterol Hepatol. 2019 Aug;17(9):1655-1668.e3. doi: 10.1016/j.cgh.2019.03.037. Epub 2019 Mar 27.

8.

Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease.

Vasudevan A, Raghunath A, Anthony S, Scanlon C, Sparrow MP, Gibson PR, van Langenberg DR.

Dig Dis Sci. 2019 Jun;64(6):1622-1631. doi: 10.1007/s10620-018-5422-8. Epub 2018 Dec 17.

PMID:
30560332
9.
10.

Should we set-up routine screening for primary sclerosing cholangitis in all IBD patients?

Bouguen G, Sparrow MP, Roblin X.

Dig Liver Dis. 2018 Nov;50(11):1176-1177. doi: 10.1016/j.dld.2018.07.043. Epub 2018 Aug 9. No abstract available.

11.

Editorial: an argument for low-dose thiopurine allopurinol combination use as first-line therapy in inflammatory bowel disease-authors' reply.

Friedman AB, Sparrow MP.

Aliment Pharmacol Ther. 2018 Jul;48(1):98-99. doi: 10.1111/apt.14798. No abstract available.

12.

6-Thioguanine Nucleotide Levels Are Associated With Mucosal Healing in Patients With Crohn's Disease.

Mao R, Guo J, Luber R, Chen BL, He Y, Zeng ZR, Ben-Horin S, Sparrow MP, Roblin X, Chen MH.

Inflamm Bowel Dis. 2018 Nov 29;24(12):2621-2627. doi: 10.1093/ibd/izy173.

PMID:
29788262
13.

Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions.

Ward MG, Sparrow MP, Roblin X.

Therap Adv Gastroenterol. 2018 May 8;11:1756284818772786. doi: 10.1177/1756284818772786. eCollection 2018. Review.

14.

Editorial: clinical trials in IBD-how much of a difference is enough?

Sparrow MP.

Aliment Pharmacol Ther. 2018 Apr;47(7):1032-1033. doi: 10.1111/apt.14574. No abstract available.

15.

Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit All.

Melmed GY, Kaplan GG, Sparrow MP, Velayos FS, Baidoo L, Bressler B, Cheifetz AS, Devlin SM, Irving PM, Jones J, Kozuch PL, Raffals LE, Siegel CA.

Clin Gastroenterol Hepatol. 2018 Nov;16(11):1829-1831. doi: 10.1016/j.cgh.2018.02.036. Epub 2018 Mar 2.

PMID:
29505910
16.

Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study).

Friedman AB, Brown SJ, Bampton P, Barclay ML, Chung A, Macrae FA, McKenzie J, Reynolds J, Gibson PR, Hanauer SB, Sparrow MP.

Aliment Pharmacol Ther. 2018 Apr;47(8):1092-1102. doi: 10.1111/apt.14571. Epub 2018 Feb 21.

17.

Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease: Is the Difference Real?

Mogilevski T, Sparrow MP.

Dig Dis Sci. 2018 May;63(5):1094-1096. doi: 10.1007/s10620-018-4952-4. No abstract available.

PMID:
29417327
18.

Therapeutic drug monitoring in inflammatory bowel disease: too little too early?-comments on the American Gastroenterology Association Guideline.

Su HY, Ward MG, Sparrow MP.

Transl Gastroenterol Hepatol. 2017 Dec 19;2:113. doi: 10.21037/tgh.2017.12.05. eCollection 2017. No abstract available.

19.

Predicting response after infliximab salvage in acute severe ulcerative colitis.

Choy MC, Seah D, Gorelik A, An YK, Chen CY, Macrae FA, Sparrow MP, Connell WR, Moore GT, Radford-Smith G, Van Langenberg DR, De Cruz P.

J Gastroenterol Hepatol. 2018 Jul;33(7):1347-1352. doi: 10.1111/jgh.14072. Epub 2018 Feb 27.

PMID:
29266456
20.

Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study.

Beswick L, Rosella O, Rosella G, Headon B, Sparrow MP, Gibson PR, van Langenberg DR.

J Crohns Colitis. 2018 Feb 28;12(3):289-297. doi: 10.1093/ecco-jcc/jjx146.

PMID:
29121178
21.

Anti-TNF Re-induction Is as Effective, Simpler, and Cheaper Compared With Dose Interval Shortening for Secondary Loss of Response in Crohn's Disease.

Srinivasan A, Vasudevan A, McFarlane A, Sparrow MP, Gibson PR, Van Langenberg DR.

J Crohns Colitis. 2018 Feb 28;12(3):280-288. doi: 10.1093/ecco-jcc/jjx144.

PMID:
29077839
22.

New onset vitiligo following commencement of infliximab in Crohn disease.

Luber RP, Chamberlain AJ, Sparrow MP.

Intern Med J. 2017 Aug;47(8):972-973. doi: 10.1111/imj.13498. No abstract available.

PMID:
28782213
23.

Examining maintenance care following infliximab salvage therapy for acute severe ulcerative colitis.

Seah D, Choy MC, Gorelik A, Connell WR, Sparrow MP, Van Langenberg D, Hebbard G, Moore G, De Cruz P.

J Gastroenterol Hepatol. 2018 Jan;33(1):226-231. doi: 10.1111/jgh.13850.

PMID:
28618062
24.

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.

Vermeire S, Sandborn WJ, Danese S, Hébuterne X, Salzberg BA, Klopocka M, Tarabar D, Vanasek T, Greguš M, Hellstern PA, Kim JS, Sparrow MP, Gorelick KJ, Hinz M, Ahmad A, Pradhan V, Hassan-Zahraee M, Clare R, Cataldi F, Reinisch W.

Lancet. 2017 Jul 8;390(10090):135-144. doi: 10.1016/S0140-6736(17)30930-3. Epub 2017 May 17. Erratum in: Lancet. 2019 Dec 22;392(10165):2696.

PMID:
28527704
25.

The need for better preventative strategies for inflammatory bowel disease patients at risk of herpes zoster virus.

Bye WA, Sparrow MP, Connor SJ, Andrews JM, Ellard K, Ng W, Hume G, Antoniades S, Walsh AJ.

Intern Med J. 2017 Nov;47(11):1263-1269. doi: 10.1111/imj.13488.

PMID:
28516725
26.

Fecal Calprotectin Is Not Affected by Pregnancy: Clinical Implications for the Management of Pregnant Patients with Inflammatory Bowel Disease.

Julsgaard M, Hvas CL, Gearry RB, Vestergaard T, Fallingborg J, Svenningsen L, Kjeldsen J, Sparrow MP, Wildt S, Kelsen J, Bell SJ.

Inflamm Bowel Dis. 2017 Jul;23(7):1240-1246. doi: 10.1097/MIB.0000000000001136.

PMID:
28498159
27.

Editorial: variability in adalimumab trough and peak serum concentrations - authors' reply.

Ward MG, Gibson PR, Sparrow MP.

Aliment Pharmacol Ther. 2017 Jun;45(11):1476-1477. doi: 10.1111/apt.14091. No abstract available.

28.

Editorial: international consensus in clinical trial end-points in ulcerative colitis - clarity or just a step in clearing the fog?

Christensen B, Sparrow MP.

Aliment Pharmacol Ther. 2017 May;45(9):1274-1275. doi: 10.1111/apt.14007. No abstract available.

29.

Adalimumab in ulcerative colitis - efficacy, safety and optimization in the era of treat-to target.

Sparrow MP.

Expert Opin Biol Ther. 2017 May;17(5):613-621. doi: 10.1080/14712598.2017.1309390. Epub 2017 Mar 28. Review.

PMID:
28316250
30.

Is there a role for thioguanine therapy in IBD in 2017 and beyond?

Taylor KM, Ward MG, Blaker PA, Sparrow MP.

Expert Rev Gastroenterol Hepatol. 2017 May;11(5):473-486. doi: 10.1080/17474124.2017.1294062. Epub 2017 Feb 20. Review.

PMID:
28276819
31.

Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease.

Ward MG, Thwaites PA, Beswick L, Hogg J, Rosella G, Van Langenberg D, Reynolds J, Gibson PR, Sparrow MP.

Aliment Pharmacol Ther. 2017 Apr;45(8):1135-1145. doi: 10.1111/apt.13992. Epub 2017 Feb 27.

32.

Serologic antibodies in relation to outcome in postoperative Crohn's disease.

Hamilton AL, Kamm MA, De Cruz P, Wright EK, Selvaraj F, Princen F, Gorelik A, Liew D, Lawrance IC, Andrews JM, Bampton PA, Sparrow MP, Florin TH, Gibson PR, Debinski H, Gearry RB, Macrae FA, Leong RW, Kronborg I, Radford-Smith G, Selby W, Bell SJ, Brown SJ, Connell WR.

J Gastroenterol Hepatol. 2017 Jun;32(6):1195-1203. doi: 10.1111/jgh.13677.

PMID:
27976801
33.

Editorial: adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.

Christensen B, Sparrow MP.

Aliment Pharmacol Ther. 2017 Jan;45(1):178-179. doi: 10.1111/apt.13842. No abstract available.

34.

B-Cell Dysregulation in Crohn's Disease Is Partially Restored with Infliximab Therapy.

Timmermans WM, van Laar JA, van der Houwen TB, Kamphuis LS, Bartol SJ, Lam KH, Ouwendijk RJ, Sparrow MP, Gibson PR, van Hagen PM, van Zelm MC.

PLoS One. 2016 Jul 28;11(7):e0160103. doi: 10.1371/journal.pone.0160103. eCollection 2016.

35.

Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results.

Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin SM, Raffals LE, Vande Casteele N, Mould DR, Colombel JF, Dubinsky M, Sandborn WJ, Siegel CA.

Clin Gastroenterol Hepatol. 2016 Sep;14(9):1302-9. doi: 10.1016/j.cgh.2016.05.010. Epub 2016 May 14.

PMID:
27189916
36.

Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.

Julsgaard M, Christensen LA, Gibson PR, Gearry RB, Fallingborg J, Hvas CL, Bibby BM, Uldbjerg N, Connell WR, Rosella O, Grosen A, Brown SJ, Kjeldsen J, Wildt S, Svenningsen L, Sparrow MP, Walsh A, Connor SJ, Radford-Smith G, Lawrance IC, Andrews JM, Ellard K, Bell SJ.

Gastroenterology. 2016 Jul;151(1):110-9. doi: 10.1053/j.gastro.2016.04.002. Epub 2016 Apr 8.

PMID:
27063728
37.

Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness Panel.

Devlin SM, Melmed GY, Irving PM, Rubin DT, Kornbluth A, Kozuch PL, Raffals LE, Velayos FS, Sparrow MP, Baidoo L, Bressler B, Cheifetz AS, Jones J, Kaplan GG, Siegel CA.

Inflamm Bowel Dis. 2016 Jun;22(6):1418-24. doi: 10.1097/MIB.0000000000000764.

PMID:
27057680
38.

Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis.

Taylor KM, Sparrow MP.

Aliment Pharmacol Ther. 2016 May;43(9):1016-7. doi: 10.1111/apt.13575. No abstract available.

39.

A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease.

Varma P, Paul E, Huang C, Headon B, Sparrow MP.

Intern Med J. 2016 Jul;46(7):798-804. doi: 10.1111/imj.13040.

PMID:
26865349
40.

How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?

Ward MG, Irving PM, Sparrow MP.

World J Gastroenterol. 2015 Oct 28;21(40):11331-42. doi: 10.3748/wjg.v21.i40.11331. Review.

41.

Editorial: diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases.

Taylor KM, Sparrow MP.

Aliment Pharmacol Ther. 2015 Jul;42(1):119-20. doi: 10.1111/apt.13235. No abstract available.

42.

Lipidomic Profiling in Inflammatory Bowel Disease: Comparison Between Ulcerative Colitis and Crohn's Disease.

Fan F, Mundra PA, Fang L, Galvin A, Moore XL, Weir JM, Wong G, White DA, Chin-Dusting J, Sparrow MP, Meikle PJ, Dart AM.

Inflamm Bowel Dis. 2015 Jul;21(7):1511-8. doi: 10.1097/MIB.0000000000000394.

PMID:
25895111
43.

Effect of intestinal resection on quality of life in Crohn's disease.

Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Sparrow MP, Florin TH, Gibson PR, Debinski H, Gearry RB, Macrae FA, Leong RW, Kronborg I, Radford-Smith G, Selby W, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Desmond PV.

J Crohns Colitis. 2015 Jun;9(6):452-62. doi: 10.1093/ecco-jcc/jjv058. Epub 2015 Apr 8.

PMID:
25855073
44.

Compassionate access anti-tumour necrosis factor-α therapy for ulcerative colitis in Australia: the benefits to patients.

Costello SP, Ghaly S, Beswick L, Pudipeddi A, Agarwal A, Sechi A, O'Connor S, Connor SJ, Sparrow MP, Bampton P, Walsh AJ, Andrews JM; Australian Inflammatory Bowel Disease Association (AIBDA).

Intern Med J. 2015 Jun;45(6):659-66. doi: 10.1111/imj.12732.

PMID:
25732268
45.

Optimizing conventional medical therapies in inflammatory bowel disease in 2014.

Asthana AK, Sparrow MP, Peyrin-Biroulet L.

Curr Drug Targets. 2014;15(11):1002-10. Review.

PMID:
25219568
46.

Pharmacokinetics in IBD: ready for prime time?

Roblin X, Rinaudo M, Sparrow MP, Moreau A, Phelip JM, Genin C, Lamarque D, Paul S.

Curr Drug Targets. 2014;15(11):1049-55. Review.

PMID:
25173707
47.

Editorial: Escalation to weekly dosing in adalimumab-treated patients with active ulcerative colitis.

Ward MG, Sparrow MP.

Aliment Pharmacol Ther. 2014 Sep;40(6):730-1. doi: 10.1111/apt.12896. No abstract available.

48.

The role of thiopurine metabolite monitoring in inflammatory bowel disease.

Beswick L, Friedman AB, Sparrow MP.

Expert Rev Gastroenterol Hepatol. 2014 May;8(4):383-92. doi: 10.1586/17474124.2014.894878. Epub 2014 Mar 31. Review.

PMID:
24684593
49.

The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders.

Friedman AB, Sparrow MP, Gibson PR.

Int J Rheum Dis. 2014 Feb;17(2):132-41. Review.

PMID:
24618304
50.

A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy.

Forbes GM, Sturm MJ, Leong RW, Sparrow MP, Segarajasingam D, Cummins AG, Phillips M, Herrmann RP.

Clin Gastroenterol Hepatol. 2014 Jan;12(1):64-71. doi: 10.1016/j.cgh.2013.06.021. Epub 2013 Jul 19.

PMID:
23872668

Supplemental Content

Loading ...
Support Center